|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2100051862 |
|
最近更新日期: Date of Last Refreshed on: |
2021-10-08 00:11:58 |
|
注册时间: Date of Registration: |
2021-10-08 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
房颤射频消融术+左心耳封堵术与单纯射频消融术相比对于左心功能和结构的影响:一项随机对照研究 |
|
Public title: |
Effect on The Function and Structure of Left Atrial:Radiofrequency Ablation with Left Atrial Appendage Occlusion Compared with Radiofrequency Ablation Alone:A RCT Study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
房颤射频消融术+左心耳封堵术与单纯射频消融术相比对于左心功能和结构的影响 |
|
Scientific title: |
Effect on The Function and Structure of Left Atrial:Radiofrequency Ablation with Left Atrial Appendage Occlusion Compared with Radiofrequency Ablation Alone |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
李奕含 |
研究负责人: |
李奕含 |
|
Applicant: |
Li Yihan |
Study leader: |
Li Yihan |
|
申请注册联系人电话: Applicant telephone: |
15098750037 |
研究负责人电话:
Study leader's |
15098750037 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
15098750037@163.com |
研究负责人电子邮件: Study leader's E-mail: |
15098750037@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
山东省济南市历城区山大路街道山大南路27号山东大学中心校区 |
研究负责人通讯地址: |
山东省济南市历城区山大路街道山大南路27号山东大学中心校区 |
|
Applicant address: |
Central Campus of Shandong University,Licheng District,Jinan city,Shandong Province |
Study leader's address: |
Central Campus of Shandong University,Licheng District,Jinan city,Shandong Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
山东大学 |
||
|
Applicant's institution: |
Shandong University |
||
|
研究负责人所在单位: |
|
||
|
Affiliation of the Leader: |
|
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2019094 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
山东大学齐鲁医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Shandong University Qilu Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
1990-01-01 00:00:00 | ||
|
伦理委员会联系人: |
田辉 |
||
|
Contact Name of the ethic committee: |
Tian Hui |
||
|
伦理委员会联系地址: |
山东省济南市历下区文化西路山东大学齐鲁医院 |
||
|
Contact Address of the ethic committee: |
Shandong University Qilu Hospital,LIxia District,Jinan city,Shandong Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
山东大学 |
||||||||||||||||||||||
|
Primary sponsor: |
Shandong University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
山东省济南市历下区文化西路44号山东大学趵突泉校区 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Baotuquan Campus,Shandong University,No.44 west Wenhua Road,Lixia District,Jinan city,Shandong Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
山东大学齐鲁医院 |
||||||||||||||||||||||
|
Source(s) of funding: |
Qilu Hosptial |
||||||||||||||||||||||
|
研究疾病: |
心房颤动 |
||||||||||||||||||||||
|
Target disease: |
Atrial Fibrillation |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
评估房颤射频消融术+左心耳封堵术与单纯房颤射频消融术相比对左心功能和结构的影响。 |
||||||||||||||||||||||
|
Objectives of Study: |
To evaluate effect on The Function and Structure of Left Atrial:Radiofrequency Ablation(RA) with Left Atrial Appendage Occlusion Compared with Radiofrequency Ablation Alone. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
(1)年龄≥18岁;(2)症状性抗心律失常药物无效的非瓣膜性房颤(NVAF);(3)一个或多个CHA2DS2-VASc危险因素;高血压、肝肾功能异常、中风、出血史或易感性、不稳定的国际标准化比率、65岁以上以及药物或酒精摄入量(4)高出血风险评分≥3或以前的大出血事件;(5)首选LAAO治疗作为长期口服抗凝药物的替代品 |
||||||||||||||||||||||
|
Inclusion criteria |
(1)aged ≥18 years; (2) symptomatic nonvalvular atrial fibrillation (NVAF) refractory to antiarrhythmic drugs; (3) one or more CHA2DS2-VASc risk factors;(4) high bleeding risk pr dicted by a HASBLED [Hypertension, Abnormal liver and renal function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly age over 65 years and Drugs or alcohol intake] score ≥ 3 or previous major bleeding event during anticoagulation therapy; (5) preferred LAAO treatment as an alternative to long-term oral anticoagulants |
||||||||||||||||||||||
|
排除标准: |
排除标准为左心房血栓的发生、显著的瓣膜性心脏病、LA增大(≥55mm)和额外的消融术或CFAE消融策略. |
||||||||||||||||||||||
|
Exclusion criteria: |
The exclusion criteria were the occurrence of LA thrombus,significant valvular heart disease, an enlarged LA (≥55 mm) and additional ablation lines or CFAE ablation strategy. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2021-10-04 00:00:00至 To 2023-10-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2021-10-04 00:00:00 至 To 2023-10-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由研究负责人用计算机产生随机序列,为随机对照研究。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The study leader uses a computer to generate random sequences.It is a RCT study. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2024-03公开原始数据 方式:利用临床试验公共管理平台并向公众开放查询 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
We will publish IPD in 2024.03.And we will use Public management platform for clinical trials to show for the public. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病历记录表+基于互联网的EDC系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF+EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |